Children achieve time in range mirroring well-controlled adults for the first time in real-world study of the minimed™ 780g system

Harder to manage pediatric and adolescent patients achieve 74% time in range, and 82% overnight time in range, well surpassing clinical consensus guidelines for glycemic control dublin, oct. 19, 2021 /prnewswire/ -- medtronic plc (nyse: mdt), a leading global healthcare technology company, recently announced one-year, real-world clinical data on 3,211 pediatric and adolescent patients with type 1 diabetes 15 years old and below using the minimed™ 780g system1 with the guardian™ sensor 3. data on this subset of patients on the system in europe showed an average time in range of 74% — surpassing clinical consensus guidelines and closely mirroring time in range for adults at 77%.
MDT Ratings Summary
MDT Quant Ranking